PROducing More Evidence to Reduce Glucocorticoids in Systemic Lupus Erythematosus: Putting Patient-Reported Outcomes in the Picture
Do glucocorticoids (GCs) affect patient-reported outcomes (PROs) in patients with systemic lupus erythematosus (SLE), even if they have achieved disease activity goals? This is the question addressed in a new study by Singh et al<sup>1</sup> published in this issue of <i>The Journal of Rheumatology</i>.
Authors
- Eric Francis Morand (ORCID: https://orcid.org/0000-0002-9507-3338)
- Sarah A. Jones (ORCID: https://orcid.org/0000-0001-9571-3289)
Institutions
- Monash Health (AU)
- Monash University (AU)
Publication Details
- Journal
- The Journal of Rheumatology
- Published
- 2026-07-01
- DOI
- https://doi.org/10.3899/jrheum.2026-0502
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00